A clinical trial study, entitled “Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)”, has reported topline results… Read More »Phased I/II clinical trial results for treatment of wet AMD with topical small molecule inhibitor of integrin αvβ3
Foundation Fighting Blindness USA (FFB), a US patient organisation advocating supports and research for individuals with retinal diseases, has openly criticized plans by the Trump… Read More »Patient organization fights to preserve pharmaceutical tax credits for development of orphan therapies in ophthalmology
Positive preliminary findings have been reported from Phase I and Phase 2 clinical research using retinal pigment epithelial (RPE) cells derived from embryonic stem cells.… Read More »Stem cell therapy clinical trial demonstrates safety and potential efficacy in small numbers of patients
A new antibody drug (lampalizumab) targeting geographic atrophy in age related macular degeneration has missed its primary endpoint in two pivotal Phase III studies comprising… Read More »New geographic atrophy drug for AMD fails to meet primary endpoint in age-related macular degeneration
An October meeting of the Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee has unanimously recommended (16-0) approval of a new… Read More »Patient reported outcomes in retinal gene therapy study make significant impact on regulatory assessment
A complement 3 (C3) inhibitor (APL-2) has shown significant results in the experimental treatment of geographic atrophy. In the Phase II multi-center, randomized, single-masked, sham-controlled… Read More »Complement C3 inhibitor (APL-2) meets primary end-point in Phase II clinical trial to treat geographic atrophy
A systematic review and meta-analysis to determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD has found… Read More »Systematic review of antioxidant vitamin and mineral use in preventing AMD suggests no benefit when analysed in >76,000 people
The results of long-term use of aflibercept in patients with macular edema has inidcated that the need for retreatment appears to be substantially reduced in… Read More »Long-term outcomes with aflibercept in diabetic macular edema (DME) – 5 year outcomes reported through extension of previous study
The Clinical Research Institute (CRI) of the Foundation Fighting Blindness (FFB) has announced the enrollment of the first patient in a 4-year study to delineate… Read More »International clinical study, supported by Foundation Fighting Blindness, aims to establish the natural history of Usher syndrome type 2A
Results from a Phase II multicentre randomised trial, which had enrolled 67 patients, with macular telangiectasia 2, has reported meeting its primary endpoint, defined as… Read More »Phase II results from encapsulated cell therapy technology show benefit in the treatment of patients with macular telangiectasia 2